Pancreatic Neoplasms
297
38
49
139
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
35 trials with published results (12%)
Research Maturity
139 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
27 terminated out of 297 trials
83.7%
-2.8% vs benchmark
6%
17 trials in Phase 3/4
25%
35 of 139 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 139 completed trials
Clinical Trials (297)
Determining Individualized Cancer Therapy in Pancreatic Cancer
Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
Microplastics in Pancreas: Oncologic and Metabolic Impact
Prospective Study FNB, Is It Time To Abandon Cytological Assessment
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
EUS-guided RFA for Pancreatic Neoplasms
PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts
Operative Risk After Pancreatic Surgery in Patients With End Stage Renal Disease
SBRT for Liver Tumors, Liver Metastases, and Pancreatic Tumors
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma